Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

VRTX

Vertex Pharmaceuticals, Inc

Feb 07 • 04:00PM ET

469.32

Dollar change -11.84
Percentage change -2.46	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB GILD AMGN REGN MRNA INCY ALNY NBIX EXEL

| Held by: VTI VOO QQQ SPY IVV VUG XLV IBB VHT QQQM

Scroll to Statements

Index	NDX, S&P 500	P/E	-	EPS (ttm)	-1.99	Insider Own	0.26%	Shs Outstand	257.74M	Perf Week	1.65%
Market Cap	120.86B	Forward P/E	25.20	EPS next Y	18.63	Insider Trans	-3.91%	Shs Float	256.85M	Perf Month	14.94%
Income	-479.80M	PEG	-	EPS next Q	4.02	Inst Own	92.36%	Short Float	1.71%	Perf Quarter	-6.11%
Sales	10.62B	P/S	11.38	EPS this Y	-96.81%	Inst Trans	-0.37%	Short Ratio	2.68	Perf Half Y	0.74%
Book/sh	60.65	P/B	7.74	EPS next Y	3734.84%	ROA	-2.18%	Short Interest	4.39M	Perf Year	12.78%
Cash/sh	25.37	P/C	18.50	EPS next 5Y	10.73%	ROE	-2.99%	52W Range	377.85 - 519.88	Perf YTD	16.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	11.42%	ROI	-2.77%	52W High	-9.73%	Beta	0.42
Dividend TTM	-	Quick Ratio	2.20	Sales past 5Y	25.08%	Gross Margin	86.11%	52W Low	24.21%	ATR (14)	12.46
Dividend Ex-Date	-	Current Ratio	2.47	EPS Y/Y TTM	-113.76%	Oper. Margin	-2.90%	RSI (14)	62.06	Volatility	2.61% 2.59%
Employees	5400	Debt/Eq	0.11	Sales Y/Y TTM	10.96%	Profit Margin	-4.52%	Recom	1.92	Target Price	501.25
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	0.82%	Payout	0.00%	Rel Volume	0.73	Prev Close	481.16
Sales Surprise	3.22%	EPS Surprise	7.41%	Sales Q/Q	11.86%	Earnings	Feb 10 AMC	Avg Volume	1.64M	Price	469.32
SMA20	6.05%	SMA50	6.62%	SMA200	1.79%	Trades		Volume	1,191,949	Change	-2.46%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$460
Dec-20-24	Reiterated	H.C. Wainwright	Buy	$600 → $535
Dec-19-24	Downgrade	Oppenheimer	Outperform → Perform
Dec-09-24	Upgrade	Jefferies	Hold → Buy	$500 → $550
Nov-14-24	Initiated	Citigroup	Buy	$575
Oct-16-24	Initiated	Scotiabank	Sector Perform
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-05-24	Downgrade	Barclays	Overweight → Equal Weight	$472 → $509
Jun-27-24	Initiated	Redburn Atlantic	Buy	$545
Apr-11-24	Upgrade	Evercore ISI	In-line → Outperform	$438
Feb-15-24	Initiated	Wolfe Research	Outperform	$515
Feb-06-24	Downgrade	Evercore ISI	Outperform → In-line	$436 → $438
Feb-02-24	Downgrade	Bernstein	Outperform → Mkt Perform
Jan-31-24	Downgrade	Robert W. Baird	Neutral → Underperform	$325
Jan-31-24	Downgrade	Maxim Group	Buy → Hold
Jan-24-24	Downgrade	Canaccord Genuity	Hold → Sell	$332 → $379
Dec-14-23	Reiterated	RBC Capital Mkts	Sector Perform	$347 → $379
May-30-23	Initiated	William Blair	Outperform	$382
May-04-23	Resumed	Piper Sandler	Overweight	$385
Mar-21-23	Initiated	Bernstein	Outperform	$344

Show Previous Ratings

Feb-05-25 09:15AM	Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics (Zacks)
Feb-04-25 07:10AM	Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now? (Motley Fool)
Feb-03-25 05:50PM	Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note (Zacks)
09:30AM	3 Magnificent Stocks to Buy and Hold Forever (Motley Fool)
09:03AM	Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains? (Zacks)
08:06AM	Loading…
Feb-02-25 08:06AM	Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy? (Motley Fool)
05:35AM	Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? (Motley Fool)
Feb-01-25 09:05AM	Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank (TipRanks)
Jan-31-25 04:17PM	These Stocks Moved the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More (Barrons.com) +5.31%
04:11PM	How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter (Investor's Business Daily)
12:38PM	These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More (Barrons.com)
12:16PM	AbbVie, Vertex's Journavx, Exxon and Chevron: Market Minute (Yahoo Finance Video)
12:08PM	Vertex stock jumps on FDA approval of new non-opioid painkiller (Yahoo Finance Video)
11:09AM	Vertex Pharmaceuticals CEO on non-opioid painkiller: It's safe, effective and non-addictive (CNBC TV)
10:59AM	No Major Catalyst, Wells Fargo Downgraded Vertex (GuruFocus.com)
10:57AM	Loading…
10:57AM	Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller (Barrons.com)
10:34AM	The FDA approved a new non-opioid painkiller. Its maker's stock is rising (Quartz)
09:56AM	Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval (Investopedia)
09:47AM	Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller (Investor's Business Daily)
07:47AM	NHS England to offer Casgevy for sickle cell disease patients (Pharmaceutical Technology)
04:36AM	FDA approves Vertexs acute pain treatment Journavx (Pharmaceutical Technology)
02:00AM	Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease in England (Business Wire)
Jan-30-25 07:13PM	Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug (The Wall Street Journal)
06:25PM	Vertex Announces FDA Approval of JOURNAVX (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain (Business Wire)
02:50PM	Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX)'s Suzetrigine: 'I Don't See A Lot Of Upside Because That Was The Drug Of The Future For Vertex' (Insider Monkey)
Jan-28-25 06:00PM	Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
09:00AM	Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know (Zacks)
Jan-27-25 10:00AM	Earnings Preview: Vertex Pharmaceuticals (VRTX) Q4 Earnings Expected to Decline (Zacks)
07:30AM	Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10 (Business Wire)
Jan-26-25 06:30AM	Is Vertex Pharmaceuticals Stock a Buy in 2025? (Motley Fool)
11:15AM	Loading…
Jan-25-25 11:15AM	Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever. (Motley Fool)
Jan-24-25 04:15AM	2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher (Motley Fool)
Jan-22-25 06:00PM	Vertex Pharmaceuticals (VRTX) Advances But Underperforms Market: Key Facts (Zacks)
Jan-21-25 06:22PM	Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever (Motley Fool)
Jan-18-25 06:40AM	3 Unstoppable Stocks to Buy in 2025 (Motley Fool)
Jan-16-25 06:00PM	Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know (Zacks)
05:49AM	Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30? (Motley Fool)
Jan-15-25 07:31PM	Analyst Report: Vertex Pharmaceuticals Incorporated (Morningstar Research)
09:00AM	Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock (Zacks)
Jan-14-25 02:47PM	Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials (Benzinga)
Jan-13-25 04:48AM	My 3 Highest-Conviction Growth Stocks to Buy in 2025 (Motley Fool)
Jan-12-25 05:01PM	Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings (Business Wire)
Jan-11-25 07:41AM	Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement (TipRanks)
Jan-10-25 05:50PM	Vertex Pharmaceuticals (VRTX) Stock Moves -0.62%: What You Should Know (Zacks)
08:42AM	Vertex Pharmaceuticals Incorporated (VRTX) Slid due to Setbacks In Clinical Trials (Insider Monkey)
07:30AM	Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (Business Wire)
07:30AM	Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore (Business Wire)
Jan-08-25 07:21AM	Vertex and Orna sign partnership to improve efficiencies of gene therapies (Pharmaceutical Technology)
Jan-07-25 07:19AM	Vertex, startup Orna to partner on gene editing research (BioPharma Dive)
07:00AM	Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) (PR Newswire)
Jan-06-25 06:00PM	Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
Jan-01-25 12:43PM	Jim Cramer's Take on Vertex Pharmaceuticals (VRTX): Bold Predictions for the Future (Insider Monkey)
09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Dec-31-24 06:00PM	Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors (Zacks)
Dec-30-24 08:30AM	Is the Options Market Predicting a Spike in Vertex Pharmaceuticals (VRTX) Stock? (Zacks)
Dec-28-24 08:00AM	Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip (Motley Fool)
Dec-26-24 08:30AM	Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip (Motley Fool)
Dec-25-24 07:51AM	Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): This Is Hardly Down For The Year. I Think It Can Still Go Lower (Insider Monkey)
07:51AM	Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): and#8216;This Is Hardly Down For The Year. I Think It Can Still Go Lower' (Insider Monkey)
06:30AM	Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst (Yahoo Finance Video)
Dec-24-24 11:02PM	Will Vertex Pharmaceuticals Incorporated (VRTX) Make You Rich In 2025? (Insider Monkey)
05:50PM	Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know (Zacks)
09:50AM	Vertex Pharmaceuticals price target lowered to $460 from $550 at Truist (TipRanks)
05:25AM	3 No-Brainer Stocks to Buy on the Latest Sell-Off (Motley Fool)
03:19AM	Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX): Their Painkiller Equaled The Placebo. And Thats Just A Shame (Insider Monkey)
Dec-23-24 04:05PM	Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13 (Business Wire)
07:39AM	Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings (Pharmaceutical Technology)
Dec-22-24 12:25PM	This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy? (Motley Fool)
04:30AM	Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025? (Motley Fool)
Dec-21-24 07:30AM	Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein (TipRanks)
06:48AM	3 Fantastic Stocks That Could Enjoy a Santa Claus Rally (Motley Fool)
04:05AM	My Top 10 Stocks to Buy for 2025 (Motley Fool)
Dec-20-24 06:16PM	Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock (Investor's Business Daily)
03:46PM	Vertex Announces US FDA Approval of ALYFTREK, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis (Business Wire)
03:35PM	Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants (Business Wire)
10:38AM	Analyst Report: Vertex Pharmaceuticals Incorporated (Morningstar Research)
08:00AM	Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? (Investor's Business Daily)
Dec-19-24 07:45PM	Analyst Report: Vertex Pharmaceuticals Incorporated (Morningstar Research) -11.37%
04:44PM	S&P 500 Gains and Losses Today: Darden Restaurants Stock Sizzles After Sales Beat (Investopedia)
04:19PM	Vertex Dives 11% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug (Investor's Business Daily)
04:05PM	Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX): I Think You Should Buy The Dip Here (Insider Monkey)
01:06PM	Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data? (Benzinga)
12:01PM	Accenture, Robinhood and Coinbase, Vertex: Market Minute (Yahoo Finance Video)
10:43AM	Vertex Pain Drug Doesnt Beat Placebo. The Company Says It Still Sees Promise. (Barrons.com)
10:33AM	Vertex's $10 Billion Blow: Painkiller Trial Results Spark Investor Panic (GuruFocus.com)
10:20AM	Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results (Investopedia)
09:16AM	Heres Why Vertex Pharmaceuticals Incorporated (VRTX) Slid in Q3 (Insider Monkey)
08:53AM	Vertex Plunges 10% After Its Non-Opioid Pain Drug Flops In Lower Back Pain (Investor's Business Daily)
08:06AM	Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging. (Investor's Business Daily)
06:00AM	Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy (Business Wire)
04:20AM	2 Unstoppable Stocks to Buy and Hold for the Next Decade (Motley Fool)
Dec-18-24 09:00AM	Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Dec-16-24 05:50PM	Why Vertex Pharmaceuticals (VRTX) Outpaced the Stock Market Today (Zacks)
04:15AM	Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030 (Motley Fool)
Dec-15-24 06:07AM	3 Unstoppable Stocks to Buy Right Now (Motley Fool)
Dec-12-24 05:51AM	The Ultimate Biotech Stock to Buy With $500 Right Now (Motley Fool)
Dec-10-24 05:50PM	Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Dec-09-24 01:23PM	Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock (Benzinga)
05:50AM	2 No-Brainer Stocks to Buy Before the End of 2024 (Motley Fool)
04:00AM	Gene therapy uptake in sickle cell stays slow, despite patient interest (BioPharma Dive)

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ALTSHULER DAVID	EVP, Chief Scientific Officer	Nov 15 '24	Sale	478.56	15	7,178	25,813	Nov 19 04:08 PM
ALTSHULER DAVID	Officer	Nov 15 '24	Proposed Sale	478.56	15	7,178		Nov 15 10:31 AM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Nov 11 '24	Sale	518.27	3,000	1,554,810	44,137	Nov 13 04:15 PM
Kewalramani Reshma	CEO & President	Nov 08 '24	Sale	515.00	15,198	7,826,970	75,772	Nov 12 04:08 PM
Kewalramani Reshma	Officer	Nov 08 '24	Proposed Sale	515.00	15,198	7,826,970		Nov 08 02:58 PM
Biller Jonathan	EVP and Chief Legal Officer	Oct 02 '24	Sale	461.66	999	461,198	16,651	Oct 03 04:12 PM
Biller Jonathan	Officer	Oct 02 '24	Proposed Sale	461.66	999	461,198		Oct 02 10:04 AM
LEIDEN JEFFREY M	Executive Chairman	Aug 30 '24	Sale	499.00	3,784	1,888,216	9,994	Sep 04 04:13 PM
Bhatia Sangeeta N.	Director	Aug 30 '24	Option Exercise	152.74	646	98,670	5,081	Sep 04 04:12 PM
Bhatia Sangeeta N.	Director	Aug 30 '24	Sale	500.00	646	323,000	4,435	Sep 04 04:12 PM
Bhatia Sangeeta N.	Director	Aug 30 '24	Proposed Sale	500.00	646	323,000		Aug 30 04:47 PM
JEFFREY LEIDEN	Director	Aug 30 '24	Proposed Sale	493.35	3,784	1,866,836		Aug 30 04:23 PM
Bhatia Sangeeta N.	Director	Aug 08 '24	Option Exercise	152.74	1,292	197,340	5,727	Aug 12 04:08 PM
Bhatia Sangeeta N.	Director	Aug 08 '24	Sale	466.29	1,292	602,447	4,435	Aug 12 04:08 PM
Bozic Carmen	EVP and CMO	Aug 07 '24	Sale	476.75	2,280	1,086,990	23,259	Aug 08 04:06 PM
Bhatia Sangeeta N.	Director	Aug 08 '24	Proposed Sale	466.29	1,292	602,447		Aug 08 11:47 AM
Bozic Carmen	Officer	Aug 07 '24	Proposed Sale	476.75	2,280	1,086,990		Aug 07 09:52 AM
SACHS BRUCE I	Director	Aug 01 '24	Option Exercise	125.71	5,295	665,634	45,295	Aug 02 04:10 PM
SACHS BRUCE I	Director	Aug 01 '24	Sale	508.00	5,295	2,689,860	40,000	Aug 02 04:10 PM
Kewalramani Reshma	CEO & President	Jul 30 '24	Sale	505.00	15,202	7,677,010	90,970	Aug 01 04:17 PM
SACHS BRUCE I	Director	Aug 01 '24	Proposed Sale	508.00	5,295	2,689,860		Aug 01 03:34 PM
Kewalramani Reshma	Officer	Jul 30 '24	Proposed Sale	505.00	15,202	7,677,010		Jul 30 03:25 PM
Bozic Carmen	EVP and CMO	Jul 24 '24	Sale	488.46	2,280	1,113,689	25,539	Jul 25 04:06 PM
Kewalramani Reshma	CEO & President	Jul 22 '24	Sale	497.00	15,202	7,555,394	106,172	Jul 24 04:05 PM
Bozic Carmen	EVP and CMO	Jul 10 '24	Sale	487.34	2,280	1,111,135	27,819	Jul 12 04:07 PM
Bozic Carmen	EVP and CMO	Jun 26 '24	Sale	471.72	2,280	1,075,522	30,099	Jun 28 04:04 PM
Bozic Carmen	EVP and CMO	Jun 12 '24	Sale	478.00	2,280	1,089,840	32,379	Jun 13 04:11 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Jun 12 '24	Sale	478.00	7,288	3,483,664	15,972	Jun 13 04:09 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Jun 03 '24	Sale	460.00	3,250	1,495,000	47,137	Jun 05 04:11 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Jun 03 '24	Sale	460.00	2,175	1,000,500	49,098	Jun 05 04:08 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	May 30 '24	Sale	439.11	2,350	1,031,908	53,523	Jun 03 04:09 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	May 31 '24	Sale	445.00	2,250	1,001,250	51,273	Jun 03 04:09 PM
Bozic Carmen	EVP and CMO	May 29 '24	Sale	445.56	2,280	1,015,877	34,659	May 31 04:19 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	May 28 '24	Sale	454.79	3,250	1,478,068	50,387	May 30 04:07 PM
Kewalramani Reshma	CEO & President	May 24 '24	Option Exercise	187.53	1,565	293,484	122,939	May 29 04:08 PM
Kewalramani Reshma	CEO & President	May 24 '24	Sale	457.00	1,565	715,205	121,374	May 29 04:08 PM
SACHS BRUCE I	Director	May 22 '24	Option Exercise	93.51	7,073	661,396	47,073	May 24 04:13 PM
SACHS BRUCE I	Director	May 22 '24	Sale	448.00	7,073	3,168,704	40,000	May 24 04:13 PM
Kewalramani Reshma	CEO & President	May 20 '24	Sale	447.00	15,202	6,795,294	121,374	May 22 04:21 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	May 15 '24	Sale	430.93	32	13,790	55,325	May 17 04:27 PM
Arbuckle Stuart A	EVP, COO	May 15 '24	Sale	430.93	69	29,734	49,691	May 17 04:24 PM
ALTSHULER DAVID	EVP, Chief Scientific Officer	May 15 '24	Sale	430.93	54	23,270	25,813	May 17 04:22 PM
Bhatia Sangeeta N.	Director	May 02 '24	Sale	402.95	467	188,178	4,435	May 03 04:05 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Apr 02 '24	Sale	419.00	240	100,560	7,500	Apr 03 04:02 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 26 '24	Sale	425.70	354	150,698	55,804	Feb 27 05:02 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Feb 26 '24	Sale	425.70	3,004	1,278,803	55,325	Feb 27 04:59 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 26 '24	Sale	425.70	883	375,893	15,972	Feb 27 04:44 PM
Arbuckle Stuart A	EVP, COO	Feb 26 '24	Sale	425.70	5,034	2,142,974	49,691	Feb 27 04:37 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 26 '24	Sale	425.70	883	375,893	7,965	Feb 27 04:29 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 26 '24	Sale	425.70	4,239	1,804,542	25,813	Feb 27 04:24 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 21 '24	Sale	421.77	360	151,837	59,467	Feb 23 04:28 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Feb 21 '24	Sale	421.77	3,191	1,345,868	60,798	Feb 23 04:20 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 21 '24	Sale	421.77	1,201	506,546	18,509	Feb 23 04:16 PM
Arbuckle Stuart A	EVP, COO	Feb 21 '24	Sale	421.77	3,603	1,519,637	59,439	Feb 23 04:12 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 21 '24	Sale	421.77	3,002	1,266,154	34,022	Feb 23 04:10 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 20 '24	Sale	420.79	480	201,979	59,827	Feb 21 04:43 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Feb 20 '24	Sale	420.79	4,254	1,790,041	63,989	Feb 21 04:38 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 20 '24	Sale	420.79	801	337,053	19,710	Feb 21 04:23 PM
Arbuckle Stuart A	EVP, COO	Feb 20 '24	Sale	420.79	4,804	2,021,475	63,042	Feb 21 04:19 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 20 '24	Sale	420.79	4,002	1,684,002	37,024	Feb 21 04:13 PM
LEIDEN JEFFREY M	Executive Chairman	Feb 15 '24	Sale	419.16	4,655	1,951,190	17,896	Feb 16 04:07 PM
LEIDEN JEFFREY M	Executive Chairman	Feb 14 '24	Sale	419.04	4,356	1,825,338	22,551	Feb 16 04:07 PM
LEIDEN JEFFREY M	Executive Chairman	Feb 12 '24	Sale	419.51	2,656	1,114,205	27,644	Feb 14 04:04 PM
LEIDEN JEFFREY M	Executive Chairman	Feb 13 '24	Sale	419.13	737	308,899	26,907	Feb 14 04:04 PM
Sachdev Amit	EVP Chief Patient & Ext Af Off	Feb 12 '24	Sale	420.24	3,222	1,354,013	74,364	Feb 13 05:15 PM
Biller Jonathan	EVP and Chief Legal Officer	Feb 12 '24	Sale	418.77	1,738	727,822	18,280	Feb 13 04:56 PM
Atkinson Edward Morrow III	EVP, Chief Technical Ops. Off.	Feb 12 '24	Sale	420.24	913	383,679	23,137	Feb 13 04:54 PM
Arbuckle Stuart A	EVP, COO	Feb 12 '24	Sale	420.24	4,295	1,804,931	75,718	Feb 13 04:51 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Feb 12 '24	Sale	420.24	1,374	577,410	9,676	Feb 13 04:48 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 12 '24	Sale	420.24	3,145	1,321,655	47,588	Feb 13 04:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VRTX

Vertex Pharmaceuticals, Inc

Upgrade your FINVIZ experience